Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Gastrointestinal Neoplasms 1Disease Progression 1Digestive System Neoplasms 1Carcinoma in Situ 1Advanced Malignant Solid Tumors 1

Interventions

Radiosurgery 2neratinib 1lutetium Lu 177 dotatate 1capivasertib 1avasopasem manganese 1Valproic Acid 1Taxes 1Sevoflurane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy 1Propofol 1Nivolumab 1Multiparametric Magnetic Resonance Imaging 1Gemcitabine 1Everolimus 1Etoposide 1Cystectomy 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cisplatin 1Carboplatin 1Blood Specimen Collection 1Biopsy 1Anesthesia, Inhalation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Disease Progression × Clinical Trials, Phase II as Topic × Clear all
NCT04503265 2025-05-01

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

Phase 1/2 Recruiting
122 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡